Exonhit presents new opportunities in blood diagnostics in neurodegenerative diseases
Identification of new markers for BSE in collaboration with Roche Applied Science
ExonHit applied its DATAS® RNA profiling technology on blood samples from bovines provided by Roche Applied Science and has identified early pre-symptomatic disease markers. The resulting RNA splicing markers were validated with 10 individual whole blood samples of BSE-infected cattle and 10 individual whole blood samples of healthy control animals by two technologically different means: micro array analysis at ExonHit and real-time PCR at Roche with the Roche LightCycler Instrument. Both validation setups revealed the same set of three markers that clearly discriminate between BSE-infected and healthy individuals. ExonHit retains all IP rights on the markers identified and diagnostics use.
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.